157 related articles for article (PubMed ID: 27335128)
1. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Kalpana SR; Bharath G; Manjunath CN; Christopher R
Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
[TBL] [Abstract][Full Text] [Related]
5. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
[TBL] [Abstract][Full Text] [Related]
8. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
10. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Sai Chandran BV; Balachander J; Adithan C
Eur J Clin Pharmacol; 2015 Feb; 71(2):173-81. PubMed ID: 25519826
[TBL] [Abstract][Full Text] [Related]
11. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
12. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
[TBL] [Abstract][Full Text] [Related]
13. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
14. Extremely low therapeutic doses of acenocoumarol in a patient with
Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
16. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
17. Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.
Lozano R; Franco ME; López L; Moneva JJ; Carrasco V; Pérez-Layo MA
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):206-10. PubMed ID: 25669612
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
19. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
[TBL] [Abstract][Full Text] [Related]
20. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.
Buzoianu AD; Militaru FC; Vesa SC; Trifa AP; Crişan S
Blood Cells Mol Dis; 2013 Mar; 50(3):166-70. PubMed ID: 23159639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
